Peptide-Drug Conjugates: A New Hope for Cancer Management

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Nov 11

PMID 36364057

Authors

Vivek P Chavda

Hetvi K Solanki

Majid Davidson

Vasso Apostolopoulos

Joanna Bojarska

Affiliations

Soon will be listed here.

Abstract

Cancer remains the leading cause of death worldwide despite advances in treatment options for patients. As such, safe and effective therapeutics are required. Short peptides provide advantages to be used in cancer management due to their unique properties, amazing versatility, and progress in biotechnology to overcome peptide limitations. Several appealing peptide-based therapeutic strategies have been developed. Here, we provide an overview of peptide conjugates, the better equivalents of antibody-drug conjugates, as the next generation of drugs for required precise targeting, enhanced cellular permeability, improved drug selectivity, and reduced toxicity for the efficient treatment of cancers. We discuss the basic components of drug conjugates and their release action, including the release of cytotoxins from the linker. We also present peptide-drug conjugates under different stages of clinical development as well as regulatory and other challenges.

Citing Articles

The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma.

Tweed J, Adams-Dam F, Bader J, Zhang Y, Allanson J, Holmes K Bioanalysis. 2025; 17(3):177-185.

PMID: 39829185 PMC: 11853612. DOI: 10.1080/17576180.2025.2452837.

Novel Cyclic Peptide-Drug Conjugate P6-SN38 Toward Targeted Treatment of EGFR Overexpressed Non-Small Cell Lung Cancer.

Bazylevich A, Miller A, Tkachenko I, Merlani M, Patsenker L, Gellerman G Pharmaceutics. 2025; 16(12.

PMID: 39771591 PMC: 11676734. DOI: 10.3390/pharmaceutics16121613.

Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.

Bauso L, La Fauci V, Munao S, Bonfiglio D, Armeli A, Maimone N Int J Mol Sci. 2024; 25(13).

PMID: 39000371 PMC: 11242495. DOI: 10.3390/ijms25137264.

Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.

Leckie J, Yokota T Molecules. 2024; 29(11).

PMID: 38893532 PMC: 11173757. DOI: 10.3390/molecules29112658.

Structure-guided design and cloning of peptide inhibitors targeting CDK9/cyclin T1 protein-protein interaction.

Taghizadeh M, Taherishirazi M, Niazi A, Afsharifar A, Moghadam A Front Pharmacol. 2024; 15:1327820.

PMID: 38808256 PMC: 11130503. DOI: 10.3389/fphar.2024.1327820.

References

Wang Z, Liang C, Shi F, He T, Gong C, Wang L . Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis. Nanoscale. 2017; 9(37):14058-14064. DOI: 10.1039/c7nr04990k. View

Murphy G, Nagase H . Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?. Nat Clin Pract Rheumatol. 2008; 4(3):128-35. DOI: 10.1038/ncprheum0727. View

Sapra R, Verma R, Maurya G, Dhawan S, Babu J, Haridas V . Designer Peptide and Protein Dendrimers: A Cross-Sectional Analysis. Chem Rev. 2019; 119(21):11391-11441. DOI: 10.1021/acs.chemrev.9b00153. View

Shirmardi S, Gandomkar M, Maragheh M, Shamsaei M . Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors. Cancer Biother Radiopharm. 2011; 26(3):309-16. DOI: 10.1089/cbr.2010.0912. View

Chen B, Dai W, He B, Zhang H, Wang X, Wang Y . Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 2017; 7(3):538-558. PMC: 5327631. DOI: 10.7150/thno.16684. View

Cheng H, Zhu J, Xu X, Qiu W, Lei Q, Han K . Activable Cell-Penetrating Peptide Conjugated Prodrug for Tumor Targeted Drug Delivery. ACS Appl Mater Interfaces. 2015; 7(29):16061-9. DOI: 10.1021/acsami.5b04517. View

Perez B, Teixeira C, Figueiras M, Gut J, Rosenthal P, Gomes J . Novel cinnamic acid/4-aminoquinoline conjugates bearing non-proteinogenic amino acids: towards the development of potential dual action antimalarials. Eur J Med Chem. 2012; 54:887-99. DOI: 10.1016/j.ejmech.2012.05.022. View

Bojarska J, Remko M, Breza M, Madura I, Fruzinski A, Wolf W . A Proline-Based Tectons and Supramolecular Synthons for Drug Design 2.0: A Case Study of ACEI. Pharmaceuticals (Basel). 2020; 13(11). PMC: 7692516. DOI: 10.3390/ph13110338. View

Capper C, Rae J, Auchus R . The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. Horm Cancer. 2016; 7(3):149-64. PMC: 4860032. DOI: 10.1007/s12672-016-0259-0. View

10.

Tang Q, Cao B, Wu H, Cheng G . Cholesterol-peptide hybrids to form liposome-like vesicles for gene delivery. PLoS One. 2013; 8(1):e54460. PMC: 3559823. DOI: 10.1371/journal.pone.0054460. View

11.

Deraos G, Chatzantoni K, Matsoukas M, Tselios T, Deraos S, Katsara M . Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. J Med Chem. 2008; 51(24):7834-42. DOI: 10.1021/jm800891n. View

12.

Das S, Al-Toubah T, El-Haddad G, Strosberg J . Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019; 13(11):1023-1031. PMC: 7227421. DOI: 10.1080/17474124.2019.1685381. View

13.

Salem A, Wang S, Billet S, Chen J, Udompholkul P, Gambini L . Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem. 2018; 61(5):2052-2061. PMC: 5907794. DOI: 10.1021/acs.jmedchem.7b01837. View

14.

Tung C, Mahmood U, Bredow S, Weissleder R . In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 2000; 60(17):4953-8. View

15.

Yi Y, Sanchez L, Gao Y, Yu Y . Janus particles for biological imaging and sensing. Analyst. 2016; 141(12):3526-39. PMC: 4899188. DOI: 10.1039/c6an00325g. View

16.

Katsara M, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V . Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J Med Chem. 2008; 51(13):3971-8. DOI: 10.1021/jm8000554. View

17.

Wang Y, Zhang X, Wan K, Zhou N, Wei G, Su Z . Supramolecular peptide nano-assemblies for cancer diagnosis and therapy: from molecular design to material synthesis and function-specific applications. J Nanobiotechnology. 2021; 19(1):253. PMC: 8381530. DOI: 10.1186/s12951-021-00999-x. View

18.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

19.

Bojarska J, New R, Borowiecki P, Remko M, Breza M, Madura I . The First Insight Into the Supramolecular System of -α-Difluoromethylornithine: A New Antiviral Perspective. Front Chem. 2021; 9:679776. PMC: 8155678. DOI: 10.3389/fchem.2021.679776. View

20.

Anami Y, Yamazaki C, Xiong W, Gui X, Zhang N, An Z . Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun. 2018; 9(1):2512. PMC: 6023893. DOI: 10.1038/s41467-018-04982-3. View